JUVENILE PARKINSONS-DISEASE AND ITS RESPONSE TO L-DOPA THERAPY

被引:2
|
作者
ASKENASY, JJM [1 ]
MENDELSON, L [1 ]
KEREN, O [1 ]
BRAUN, Z [1 ]
机构
[1] TEL AVIV UNIV,LOEWENSTEIN REHABIL HOSP,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL
关键词
Childhood appearance; circadian fluctuations; dystonic foot onset; early "on-off phenomena; familial incidence; low dose levodopa responsiveness;
D O I
10.1007/BF02251243
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Four youngsters, between the ages of 13-27 years, presented dystonic foot. Two to three years following the appearance of the dystonic foot, cogwheel rigidity and tremor appeared on the dystonic foot side. Treatment with low doses of levodopa/carbidopa consistently reversed the symptoms. "On-off" phenomena appeared in the first years of treatment and persisted for the entire period of 5 to 15 years of illness. No parkinsonian signs were present when the dystonic foot appeared. Based on our observations and on a review of the literature, we conclude that responsiveness to low doses of L-dopa is the major maker of juvenile Parkinson's disease. © 1990 Springer-Verlag.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 50 条
  • [41] L-DOPA METHYL-ESTER - A CANDIDATE FOR CHRONIC SYSTEMIC DELIVERY OF L-DOPA IN PARKINSONS-DISEASE
    COOPER, DR
    MARREL, C
    TESTA, B
    VANDEWATERBEEMD, H
    QUINN, N
    JENNER, P
    MARSDEN, CD
    CLINICAL NEUROPHARMACOLOGY, 1984, 7 (01) : 89 - 98
  • [42] PARKINSONS-DISEASE AND AMINE METABOLITES IN CEREBROSPINAL-FLUID - IMPLICATIONS FOR L-DOPA THERAPY
    KORF, J
    VANPRAAG, HM
    SCHUT, D
    NIENHUIS, RJ
    LAKKE, JPWF
    EUROPEAN NEUROLOGY, 1974, 12 (5-6) : 340 - 350
  • [43] NEUROCHEMICAL RESPONSES TO 6-HYDROXYDOPAMINE AND L-DOPA THERAPY - IMPLICATIONS FOR PARKINSONS-DISEASE
    ZIGMOND, MJ
    HASTINGS, TG
    ABERCROMBIE, ED
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 648 : 71 - 86
  • [44] MYOINTEGRATION AS A METHOD FOR QUANTIFICATION OF RIGIDITY IN PARKINSONS-DISEASE BEFORE AND AFTER L-DOPA THERAPY
    GEHLEN, W
    EISENLOH.JJ
    ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1974, 36 (04): : 439 - 439
  • [45] L-DOPA AND PARKINSONS DISEASE
    BARBEAU, A
    UNION MEDICALE DU CANADA, 1970, 99 (12): : 2195 - +
  • [46] L-DOPA IN PARKINSONS DISEASE
    CLEGHORN, RA
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1970, 102 (13) : 1410 - &
  • [47] DOES LONG-TERM L-DOPA THERAPY CAUSE DEMENTIA IN PARKINSONS-DISEASE
    MELAMED, E
    MILDWORF, B
    GLOBUS, M
    MARTINOVICH, G
    GOLDBERG, A
    NEUROLOGY, 1986, 36 (04) : 309 - 309
  • [48] L-DOPA IN PARKINSONS DISEASE
    MCDOWELL, FH
    LEE, JE
    CALIFORNIA MEDICINE, 1970, 113 (04): : 44 - &
  • [49] THE EFFECTS OF CISAPRIDE ON PLASMA L-DOPA LEVELS AND CLINICAL-RESPONSE IN PARKINSONS-DISEASE
    NEIRA, WD
    SANCHEZ, V
    MENA, MA
    DEYEBENES, JG
    MOVEMENT DISORDERS, 1995, 10 (01) : 66 - 70
  • [50] L-DOPA DOSE-RESPONSE STUDY OF REACTION-TIMES IN PARKINSONS-DISEASE
    PULLMAN, S
    WATTS, RL
    JUNCOS, JL
    CHASE, TN
    SANES, JN
    NEUROLOGY, 1986, 36 (04) : 159 - 159